Sale

Blastomycosis Market by Treatment Modalities, Patient Profile, Healthcare Settings, Application Areas, Diagnostic Approaches, Distribution Channels, Prevention and Control - Global Forecast 2025-2030

Report
181 Pages
November 2024
Region: Global
360iResearch™
ID: 6010940

UP TO €692EUR$697USD£576GBP OFF until Dec 31^st 2024

The Blastomycosis Market grew from USD 156.34 million in 2023 to USD 161.94 million in 2024. It is expected to continue growing at a CAGR of 3.38%, reaching USD 197.31 million by 2030.

Blastomycosis, a fungal infection caused by Blastomyces dermatitidis, primarily affects the lungs and can spread to other body parts, presenting a growing concern in the medical community. The necessity for effective diagnostics and treatments is driven by the rising incidence of fungal infections globally and the expanding at-risk populations, including immunocompromised individuals. Applications for addressing this condition include advancements in diagnostic technologies, therapeutic interventions, and prophylactic measures to manage and mitigate outbreaks. The end-use scope primarily targets healthcare settings such as hospitals, clinics, research institutes, and pharmaceutical companies engaged in R&D.

The market for blastomycosis-related solutions is influenced by key growth factors such as increased awareness about fungal infections, rising healthcare expenditure, and technological advancements in diagnostic procedures. Opportunities abound in the development of rapid diagnostic kits and innovative antifungal therapies that address current unmet needs.

Strategic partnerships between biotech firms and research institutions could lead to groundbreaking solutions, with potential benefits including improved patient outcomes and reduced healthcare costs. Limitations include the high cost of R&D, regulatory hurdles in drug approval pathways, and limited knowledge about the disease in non-endemic regions. These challenges necessitate a focus on comprehensive education campaigns and enhanced funding for research-focused initiatives.

In terms of innovation, novel antifungal agents, point-of-care testing devices, and telemedicine platforms present the best opportunities for market growth. Collaborations with academic and scientific communities can fuel discoveries and bolster product pipelines. The nature of this market is characterized by a blend of moderate growth and dynamic shifts due to regional epidemiological variables and evolving pathogen resistances. To capitalize, businesses should focus on diversified portfolios that address diagnostics, therapeutics, and preventative measures. This strategic approach, coupled with a strong emphasis on research and competitive pricing models, can position stakeholders for sustained success in managing blastomycosis and related fungal infections.

Understanding Market Dynamics in the Blastomycosis Market

The Blastomycosis Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Expanding healthcare infrastructure and services, particularly in rural and underserved areas.
- Increasing incidence of blastomycosis in endemic regions and rising concern among health authorities.
- Greater investment in research and development activities focused on blastomycosis treatment and prevention.
Market Restraints
- Key market restraints in the management and treatment of blastomycosis that pose significant challenges
- Significant barriers to effective blastomycosis treatment limiting progress in therapeutic solutions
- Inadequate healthcare infrastructure and facilities further exacerbating blastomycosis management issues
Market Opportunities
- Developing educational campaigns to raise awareness about blastomycosis in susceptible regions
- Collaborating with environmental agencies to understand and mitigate the ecological factors of blastomycosis
- Innovating treatment methods focusing on reducing recovery time and improving patient outcomes
Market Challenges
- Anatomizing the limited awareness of blastomycosis among healthcare professionals and the public
- Investigating the potential unknowns and challenges posed by climate change on blastomycosis prevalence
- Understanding the complexity of blastomycosis transmission pathways complicates market analysis

Exploring Porter’s Five Forces for the Blastomycosis Market

Porter’s Five Forces framework further strengthens the insights of the Blastomycosis Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Blastomycosis Market

External macro-environmental factors deeply influence the performance of the Blastomycosis Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Blastomycosis Market

The Blastomycosis Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Blastomycosis Market

The Blastomycosis Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Blastomycosis Market

The Blastomycosis Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blastomycosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Inc.

Market Segmentation & Coverage

This research report categorizes the Blastomycosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Modalities
- Antifungal Medications
  - Azole Class
  - Echinocandins
  - Polyenes
- Monotherapy Vs. Combination Therapy
  - Combination Therapy
  - Monotherapy
Patient Profile
- Age Groups
  - Adult
  - Geriatric
  - Pediatric
- Comorbidity Presence
  - Immunocompromised
  - Non-Immunocompromised
- Gender
  - Female
  - Male
Healthcare Settings
- Clinics
  - General Clinics
  - Specialized Clinics
- Homecare
  - Home Medical Services
  - Telemedicine
- Hospitals
  - Private Hospitals
  - Public Hospitals
Application Areas
- Disseminated Infection
  - Cutaneous Blastomycosis
  - Extrapulmonary Blastomycosis
- Primary Infection
  - Acute Blastomycosis
  - Chronic Blastomycosis
Diagnostic Approaches
- Laboratory-Based Testing
  - Microbial Culture
  - Nucleic Acid Testing
- Radiographic Evaluation
  - CT Scans
  - X-ray Imaging
- Symptomatic Analysis
  - Clinical Manifestations
Distribution Channels
- Offline Sales
  - Hospital Pharmacies
  - Retail Pharmacies
- Online Sales
  - Manufacturer Websites
  - Online Pharmacies
Prevention And Control
- Personal Protective Equipment
  - Clothing And Gloves
  - Respiratory Masks
- Vaccination Research
  - Prophylactic Approach
  - Therapeutic Approach

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expanding healthcare infrastructure and services, particularly in rural and underserved areas.
5.1.1.2. Increasing incidence of blastomycosis in endemic regions and rising concern among health authorities.
5.1.1.3. Greater investment in research and development activities focused on blastomycosis treatment and prevention.
5.1.2. Restraints
5.1.2.1. Key market restraints in the management and treatment of blastomycosis that pose significant challenges
5.1.2.2. Significant barriers to effective blastomycosis treatment limiting progress in therapeutic solutions
5.1.2.3. Inadequate healthcare infrastructure and facilities further exacerbating blastomycosis management issues
5.1.3. Opportunities
5.1.3.1. Developing educational campaigns to raise awareness about blastomycosis in susceptible regions
5.1.3.2. Collaborating with environmental agencies to understand and mitigate the ecological factors of blastomycosis
5.1.3.3. Innovating treatment methods focusing on reducing recovery time and improving patient outcomes
5.1.4. Challenges
5.1.4.1. Anatomizing the limited awareness of blastomycosis among healthcare professionals and the public
5.1.4.2. Investigating the potential unknowns and challenges posed by climate change on blastomycosis prevalence
5.1.4.3. Understanding the complexity of blastomycosis transmission pathways complicates market analysis
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Blastomycosis Market, by Treatment Modalities

6.1. Introduction
6.2. Antifungal Medications
6.2.1. Azole Class
6.2.2. Echinocandins
6.2.3. Polyenes
6.3. Monotherapy Vs. Combination Therapy
6.3.1. Combination Therapy
6.3.2. Monotherapy

7. Blastomycosis Market, by Patient Profile

7.1. Introduction
7.2. Age Groups
7.2.1. Adult
7.2.2. Geriatric
7.2.3. Pediatric
7.3. Comorbidity Presence
7.3.1. Immunocompromised
7.3.2. Non-Immunocompromised
7.4. Gender
7.4.1. Female
7.4.2. Male

8. Blastomycosis Market, by Healthcare Settings

8.1. Introduction
8.2. Clinics
8.2.1. General Clinics
8.2.2. Specialized Clinics
8.3. Homecare
8.3.1. Home Medical Services
8.3.2. Telemedicine
8.4. Hospitals
8.4.1. Private Hospitals
8.4.2. Public Hospitals

9. Blastomycosis Market, by Application Areas

9.1. Introduction
9.2. Disseminated Infection
9.2.1. Cutaneous Blastomycosis
9.2.2. Extrapulmonary Blastomycosis
9.3. Primary Infection
9.3.1. Acute Blastomycosis
9.3.2. Chronic Blastomycosis

10. Blastomycosis Market, by Diagnostic Approaches

10.1. Introduction
10.2. Laboratory-Based Testing
10.2.1. Microbial Culture
10.2.2. Nucleic Acid Testing
10.3. Radiographic Evaluation
10.3.1. CT Scans
10.3.2. X-ray Imaging
10.4. Symptomatic Analysis
10.4.1. Clinical Manifestations

11. Blastomycosis Market, by Distribution Channels

11.1. Introduction
11.2. Offline Sales
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.3. Online Sales
11.3.1. Manufacturer Websites
11.3.2. Online Pharmacies

12. Blastomycosis Market, by Prevention And Control

12.1. Introduction
12.2. Personal Protective Equipment
12.2.1. Clothing And Gloves
12.2.2. Respiratory Masks
12.3. Vaccination Research
12.3.1. Prophylactic Approach
12.3.2. Therapeutic Approach

13. Americas Blastomycosis Market

13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Blastomycosis Market

14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Blastomycosis Market

15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape

16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. BLASTOMYCOSIS MARKET MULTI-CURRENCY
FIGURE 2. BLASTOMYCOSIS MARKET MULTI-LANGUAGE
FIGURE 3. BLASTOMYCOSIS MARKET RESEARCH PROCESS
FIGURE 4. BLASTOMYCOSIS MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2023 VS 2030 (%)
FIGURE 21. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. BLASTOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. BLASTOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. BLASTOMYCOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BLASTOMYCOSIS MARKET DYNAMICS
TABLE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AZOLE CLASS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY NON-IMMUNOCOMPROMISED, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOME MEDICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TELEMEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CUTANEOUS BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY EXTRAPULMONARY BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ACUTE BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CHRONIC BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MICROBIAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CT SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CLINICAL MANIFESTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CLOTHING AND GLOVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY RESPIRATORY MASKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PROPHYLACTIC APPROACH, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY THERAPEUTIC APPROACH, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 156. CANADA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 157. CANADA BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 158. CANADA BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 159. CANADA BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 160. CANADA BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 161. CANADA BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 162. CANADA BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 163. CANADA BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 164. CANADA BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. CANADA BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 166. CANADA BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 167. CANADA BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 168. CANADA BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 169. CANADA BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 170. CANADA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 171. CANADA BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 172. CANADA BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 173. CANADA BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 174. CANADA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 175. CANADA BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 176. CANADA BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 177. CANADA BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 178. CANADA BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 179. CANADA BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 180. MEXICO BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 181. MEXICO BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 183. MEXICO BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 184. MEXICO BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 186. MEXICO BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 187. MEXICO BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 190. MEXICO BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 191. MEXICO BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 193. MEXICO BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 194. MEXICO BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 195. MEXICO BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 196. MEXICO BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 197. MEXICO BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 199. MEXICO BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 201. MEXICO BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 202. MEXICO BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 203. MEXICO BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 278. CHINA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 279. CHINA BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 280. CHINA BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 281. CHINA BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 282. CHINA BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 283. CHINA BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 284. CHINA BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 285. CHINA BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 286. CHINA BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 287. CHINA BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 288. CHINA BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 289. CHINA BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 290. CHINA BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 291. CHINA BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 292. CHINA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 293. CHINA BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 294. CHINA BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 295. CHINA BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 296. CHINA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 297. CHINA BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 298. CHINA BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 299. CHINA BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 300. CHINA BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 301. CHINA BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 302. INDIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 303. INDIA BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 304. INDIA BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 305. INDIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 306. INDIA BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 307. INDIA BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 308. INDIA BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 309. INDIA BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 310. INDIA BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 311. INDIA BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 312. INDIA BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. INDIA BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 314. INDIA BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 315. INDIA BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 316. INDIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 317. INDIA BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 318. INDIA BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 320. INDIA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 321. INDIA BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 322. INDIA BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 323. INDIA BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 324. INDIA BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 325. INDIA BLASTOMYCOSIS MARKET SIZE, BY VACCINATION RESEARCH, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 328. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY MONOTHERAPY VS. COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 329. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 330. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 331. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY COMORBIDITY PRESENCE, 2018-2030 (USD MILLION)
TABLE 332. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 333. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY HEALTHCARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 334. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 335. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 336. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 337. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 338. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED INFECTION, 2018-2030 (USD MILLION)
TABLE 339. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY PRIMARY INFECTION, 2018-2030 (USD MILLION)
TABLE 340. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 341. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY LABORATORY-BASED TESTING, 2018-2030 (USD MILLION)
TABLE 342. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY RADIOGRAPHIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 343. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY SYMPTOMATIC ANALYSIS, 2018-2030 (USD MILLION)
TABLE 344. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 345. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY OFFLINE SALES, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY PREVENTION AND CONTROL, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY PERSONAL PROTECTIVE EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA BLASTOMYCOSI

Companies Mentioned

AbbVie Inc.
Allergan plc
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Biogen Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Gilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	November 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 161.94 million
Forecasted Market Value ( USD ) by 2030	$ 197.31 million
Compound Annual Growth Rate	3.3%
Regions Covered	Global
No. of Companies Mentioned	20

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3522EUR$3,545USD£2,928GBP €3913EUR$3,939USD£3,254GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6231EUR$6,272USD£5,181GBP €6923EUR$6,969USD£5,756GBP

Understanding Market Dynamics in the Blastomycosis Market

Exploring Porter’s Five Forces for the Blastomycosis Market

Applying PESTLE Analysis to the Blastomycosis Market

Analyzing Market Share in the Blastomycosis Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Blastomycosis Market

Strategic Recommendations for Success in the Blastomycosis Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Executive and Consultant Guides 2024-2028

Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User - Global Forecast 2025-2030

Respiratory Infection Diagnostics Market by Test, Disease, End-User - Global Forecast 2025-2030

Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Conventional), Infection Type (UTI, Pneumonia), Product (Consumables), Type, Region, and Segment Forecasts, 2023-2030

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report by Technology (Microbiology Culture, PCR), End-use (Hospitals, Diagnostic Laboratories), Pathogen, Region, and Segment Forecasts, 2025-2030